Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BYZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Impact of non-donor specific HLA antibodies on outcomes of allogeneic hematopoietic stem cell transplantation].

  • J N Yang1
  • H Xiao1
  • X Li1
  1. 1Department of Hematology, the Third Xiangya Hospital, Central South University, Changsha 410013, China.
Read full textPDFDOICite

Abstract

We retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and completed anti-HLA antibody screening at our center between January 2016 to July 2025 to examine the impact of non-donor specific HLA antibodies (NDSA) on the clinical outcomes in this patient population and to analyze the potential efficacy of using desensitization therapies. Among the 618 patients screened patients, 379 underwent allo-HSCT. Fifty-five patients were NDSA-positive. Based on the screening results, NDSA-positive patients were divided into the following groups according to the mean fluorescence intensity (MFI) : 1 000≤MFI<10,000 and MFI≥10,000 groups. Compared with the antibody-negative group, the NDSA-positive patients were older, more likely to be female, and had a higher rate of prior pregnancy (P<0.05). In the fully matched transplants without desensitization, the 3-year overall survival (OS) was significantly lower in the NDSA-positive group (P=0.043). Stratified analysis showed that NDSA MFI of ≥10,000 was as an independent risk factor for inferior 3-year OS (HR=4.364, 95% CI: 1.041-18.291, P<0.05) and event-free survival (EFS) (HR=3.453, 95% CI: 1.035-11.518, P<0.05). In the propensity score-matched NDSA-positive cohort, the desensitization group showed numerically higher 3-year OS[100% vs (66.7±15.7) %, P=0.123] and EFS[ (83.3±15.2) % vs (53.3±17.3) %, P=0.253] than the untreated group. Our study findings suggest that NDSA MFI of ≥10,000 may be associated with poorer long-term survival in patients receiving fully matched allo-HSCT. Desensitization therapy may improve the long-term outcomes of these patients.

Related

  1. Adoptive Virus-Specific T Cell Therapy for Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation: Current Strategies and Future Perspectives
    Eva M. Weissinger, Lisa M. Schulz, Debora Basilio-Queiros +2
    BiomoleculesPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  2. Early Patient-Reported Outcomes and Graft-Versus-Host Disease as Indicators of Long-Term Quality of Life and Fatigue After Allogeneic Hematopoietic Stem Cell Transplantation: A 24-Month Prospective Study
    Gabriela Lampart, Sebastian Klich, Agnieszka Gniadek +1
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  3. The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
    Laura Diana Stocker, Lisa Thielecke, Constantin Schmitz +3
    The Cochrane Database of Systematic ReviewsPeer-reviewedPublisher termsFull textGeneral medicinePMC
  4. Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
    Wenhui Zhang, Xiaolin Ma, Xianglan Liu +6
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. [The impact of collateral CMV-seropositive and CMV-seronegative donors on the outcomes of allogeneic hematopoietic stem cell transplantation].
    J Liu, Y Y Zhang, X D Mo +10
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{yang2026impact,
  title = {{[Impact of non-donor specific HLA antibodies on outcomes of allogeneic hematopoietic stem cell transplantation].}},
  author = {J N Yang and H Xiao and X Li},
  journal = {Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
  year = {2026},
  month = aug,
  doi = {10.3760/cma.j.cn121090-20251218-00601},
  url = {https://europepmc.org/article/MED/42851182},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - [Impact of non-donor specific HLA antibodies on outcomes of allogeneic hematopoietic stem cell transplantation].
AU  - J N Yang
AU  - H Xiao
AU  - X Li
PY  - 2026
DA  - 2026/08/01
JO  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
DO  - 10.3760/cma.j.cn121090-20251218-00601
UR  - https://europepmc.org/article/MED/42851182
AB  - We retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and completed anti-HLA antibody screening at our center between January 2016 to July 2025 to examine the impact of non-donor specific HLA antibodies (NDSA) on the clinical outcomes in this patient population and to analyze the potential efficacy of using desensitization therapies. Among the 618 patients screened patients, 379 underwent allo-HSCT. Fifty-five patients were NDSA-positive. Based on the screening results, NDSA-positive patients were divided into the following groups according to the mean fluorescence intensity (MFI) : 1 000≤MFI<10,000 and MFI≥10,000 groups. Compared with the antibody-negative group, the NDSA-positive patients were older, more likely to be female, and had a higher rate of prior pregnancy (P<0.05). In the fully matched transplants without desensitization, the 3-year overall survival (OS) was significantly lower in the NDSA-positive group (P=0.043). Stratified analysis showed that NDSA MFI of ≥10,000 was as an independent risk factor for inferior 3-year OS (HR=4.364, 95% CI: 1.041-18.291, P<0.05) and event-free survival (EFS) (HR=3.453, 95% CI: 1.035-11.518, P<0.05). In the propensity score-matched NDSA-positive cohort, the desensitization group showed numerically higher 3-year OS[100% vs (66.7±15.7) %, P=0.123] and EFS[ (83.3±15.2) % vs (53.3±17.3) %, P=0.253] than the untreated group. Our study findings suggest that NDSA MFI of ≥10,000 may be associated with poorer long-term survival in patients receiving fully matched allo-HSCT. Desensitization therapy may improve the long-term outcomes of these patients.
SN  - 0253-2727
SN  - 2707-9740
ER  -